SYRE Q4 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M

Gross Profit

$45M50.0% margin

Operating Income

-$57M-63.2% margin

Net Income

-$63M-69.1% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$778M

Total Liabilities

$63M

Stockholders' Equity

$715M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$0	—
Gross Profit	$45M	$0	—
Operating Income	-$57M	-$61M	+6.7%
Net Income	-$63M	-$56M	-11.1%